in vitro News and Research

RSS

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer).

9 Jun 2015

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory.

From Illumina, Inc. 8 Jun 2015

Bio-Techne to acquire 100% ownership of Cliniqa

Bio-Techne Corporation announced today that it has agreed to acquire 100% ownership of Cliniqa Corporation. Cliniqa specializes in the manufacturing and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market.

From CLINIQA - Diagnostics Division 5 Jun 2015

Tabletop design offers greater stability, especially for small laboratory tables

The low-profile, high-density CleanBench tops offer superior damping, stiffness, and flatness in an easy-to-clean stainless steel shell and are available with or without tapped holes...

4 Jun 2015

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today reported several new customer disclosures on the use of the Company's CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials at the recent International Society for Cellular Therapy (ISCT) conference.

3 Jun 2015

Researchers transform bacteria into 'secret agents' for detecting disease

Another step forward has just been taken in the area of synthetic biology. Research teams from Inserm and CNRS (French National Centre for Scientific Research) Montpellier, in association with Montpellier Regional University Hospital and Stanford University, have transformed bacteria into "secret agents" that can give warning of a disease based solely on the presence of characteristic molecules in the urine or blood. To perform this feat, the researchers inserted the equivalent of a computer programme into the DNA of the bacterial cells.

3 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Leading antibody researchers at the University of Southampton, under the direction of Professor Mark Cragg, Professor of Experimental Cancer Research and Director of the Cancer Pathway Integrated Postgraduate Programme, today announce a three-year research collaboration with BioInvent International.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20

30 May 2015

Merck signs in vitro fertilization deal with Genea Biomedx

Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for Assisted Reproductive Treatment (ART), receives global marketing and commercialization rights to Genea Biomedx’s product portfolio.

30 May 2015

New imaging technique may improve testicular sperm extraction, reduce trauma during surgery

In the middle of Europe nearly every sixth couple in the reproductive age is involuntarily childless, in 50% due to male infertility. In about 10% of all infertile men azoospermia is diagnosed, i.e. no spermatozoa are found in the ejaculate.

30 May 2015

Scorpion venom could kill cancer cells

When the toxin invades channels in the cells with this disease produces cellular damage until killing them.

27 May 2015

$Study analyses advantages of using fractions of ejaculate in IVF$

Study analyses advantages of using fractions of ejaculate in IVF

Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.

27 May 2015

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.

27 May 2015

Alternative generic strategy for breast cancer treatment

Maxing out the inherently stressed nature of treatment-resistant breast cancer cells thwarts their adaptive ability to evolve genetic workarounds to treatment, a new study suggests.

27 May 2015

New in vitro system could become important tool in search for potential drugs against Alzheimer’s

A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between brain cells.

26 May 2015

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.

21 May 2015

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis.

19 May 2015

in vitro News and Research

Cell fusion triggers multiple genetic changes that convert normal cells to cancer cells

Merck KGaA, Darmstadt, Germany forms Global Fertility Alliance with Illumina and Genea

Bio-Techne to acquire 100% ownership of Cliniqa

Tabletop design offers greater stability, especially for small laboratory tables

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

Researchers transform bacteria into 'secret agents' for detecting disease

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

University of Southampton and BioInvent enter collaboration to develop new cancer immunotherapies

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Merck signs in vitro fertilization deal with Genea Biomedx

New imaging technique may improve testicular sperm extraction, reduce trauma during surgery

Scorpion venom could kill cancer cells

Study analyses advantages of using fractions of ejaculate in IVF

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

Alternative generic strategy for breast cancer treatment

New in vitro system could become important tool in search for potential drugs against Alzheimer’s

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Lakewood-Amedex's novel class of antimicrobials prove effective at killing MDR-TB strains

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News